SSRI Discontinuation Syndrome Management

Understanding SSRI Withdrawal Syndrome

Somatic symptoms of SSRI discontinuation syndrome include dizziness, light-headedness, nausea, fatigue, myalgias, sensory disturbances, and sleep disturbances, affecting patients taking medications such as paroxetine, fluvoxamine, and sertraline 1
Younger patients are at higher risk of severe withdrawal symptoms 1

The American Academy of Child and Adolescent Psychiatry recommends gradual tapering over months, rather than weeks, to minimize withdrawal symptoms in patients taking SSRIs such as paroxetine, fluvoxamine, and sertraline 1
A conservative starting point for tapering is to reduce the dose by approximately 10% per week, adjusting based on patient tolerance, as suggested by the American Academy of Sleep Medicine and Mayo Clinic Proceedings 2, 3
For patients on long-term treatment, consider even slower tapers of 10% per month or slower, according to Mayo Clinic Proceedings 3
The American Academy of Sleep Medicine recommends reinstituting the previous dose and slowing the rate of taper if severe symptoms develop during discontinuation 2

Monitor patients closely during tapering with more frequent follow-up appointments, as recommended by the American Academy of Sleep Medicine and Mayo Clinic Proceedings 2, 3, 4
Use standardized symptom rating scales to distinguish withdrawal from relapse, as suggested by the Journal of the American Academy of Child and Adolescent Psychiatry 1